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Harakiri Silencing Confers Apoptosis
Resistance and Enhanced Tumor Growth
The Harakiri (HRK) gene, encoding an important pro-
apoptotic mitochondrial protein of the Bcl-2 family, is
expressed in normal tissues but is decreased in many
cancers. Based on bioinformatics analysis, Xu et al (Am J
Pathol 2013, 182:84e95) hypothesized that HRK promoter
hypermethylation and inhibition of AP-2a transactivation
leads to HRK expression silencing. In a melanoma model,
HRK transcription was signiﬁcantly decreased due to aber-
rant DNA methylation of the HRK promoter, preventing
binding to and transactivation by AP-2a and resulting in
resistance to apoptosis and enhanced tumor growth. Artiﬁ-
cial overexpression of AP-2a in melanoma cells upregulated
HRK transcription, which was further restored by treatment
with the DNA methyltransferase inhibitor 5-azacytidine.
Artiﬁcial overexpression of HRK induced caspase-
dependent apoptosis, inhibited melanoma cell growth
in vitro, and markedly reduced in vivo melanoma growth.
RNA interference by siHRK or siAP-2a reversed these
effects. These novel molecular lesions may provide a ratio-
nale for HRK- and AP-2abased treatment of such affected
cancers.Deoxyribonucleotide Pools Suppress
Oncogene-Induced Senescence
Oncogene-induced senescence (OIS) depends on DNA
damage response (DDR) induction in normal human cells.
Mannava et al (Am J Pathol 2013, 182:142e151) tested the
hypothesis that at least one of the major mediators of
HRASG12V DNA damage- and senescence-inducing activity
is down-regulation of dNTP pools. Normal human ﬁbroblast
(NHF)-HRASG12V cells underexpressed two enzymes
required for de novo dNTP biosynthesis, resulting in low
dNTP levels. Chromatin at the enzymes’ gene promoters was
enriched with RB tumor suppressor protein and tri-
methylated histone H3. Ectopic co-expression of dNTP
biosynthesis enzymes or addition of deoxyribonucleosides
suppressed DNA damage, senescence-associated pheno-
types, and proliferation arrest in two types of NHF expressing
HRASG12V. However, enzyme overexpression in quiescentCopyright ª 2013 American Society for Investigative Pathology.
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unlike quiescence, OIS requires depletion of dNTP pools and
activated DNA replication. Taken together, these data pro-
vide a previously unidentiﬁed mechanism for the induction
of DNA damage- and oncogene-induced senescence.miR-150 Expression Is Decreased in Systemic
Sclerosis
Integrin overexpression in dermal ﬁbroblasts plays a key
role in systemic sclerosis (SSc) pathogenesis. Honda et al
(Am J Pathol 2013, 182:206e216) evaluated the role of
microRNAs (miRNAs) in the regulation of integrin b3 in
dermal ﬁbroblasts. Analysis of miRNA expression demon-
strated decreased miR-150 expression in SSc ﬁbroblasts
both in vivo and in vitro. Transfection of miR-150 inhibitor
into normal ﬁbroblasts induced expression of integrin b3,
phosphorylated Smad3, and type I collagen, whereas forced
overexpression of miR-150 resulted in down-regulation of
these targets in SSc ﬁbroblasts. Treatment of SSc ﬁbroblasts
with 5-aza-deoxycytdine established that miR-150 down-
regulation was the result of DNA methylation. Serum
miR-150 levels were also decreased in SSc patients, and SSc
patients with lower serum miR-150 levels had more severe
clinical manifestations. miR-150 may thus play an important
role in SSc pathogenesis via integrin b3 overexpression.Prolactin Receptor as a Biomarker in Breast
Cancer Progression
The polypeptide hormone prolactin (PRL) stimulates breast
epithelial cell growth, differentiation, and motility through
its cognate receptor PRLr, which is expressed in a majority
of breast cancers. Fiorillo et al (Am J Pathol 2013,
182:217e233) utilized a PRLr transactivation-deﬁcient
mutant to examine the role of nuclear PRLr in tumorigen-
esis and to identify novel transactivation domain (TAD)-
speciﬁc target genes. Microarray analysis revealed that PRLr
TAD affected cancer and proliferation signaling networks.
TAD mutation signiﬁcantly impaired estrogen and pro-
gesterone receptor (ERa/PR) expression and estrogen re-
sponsiveness, linking the PRLr TAD and ERa/PR. Tissue
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in nuclear PRLr TAD phosphorylation as a function of
neoplastic progression, suggesting that PRLr TAD phos-
phorylation contributes to breast cancer pathogenesis in part
through regulation of ERa and PR. These data suggest
that prolactin has potential utility as a biomarker in breast
cancer.Drug Transporters Might Be Predictive of
Outcome in HNSCC
Membrane transporter expression levels may affect the
disposition and treatment efﬁcacy of anticancer drugs in
human head and neck squamous cell carcinoma (HNSCC).
Zolk et al (Am J Pathol 2013, 182:234e243) ana-
lyzed membrane transporter gene expression proﬁles and2evaluated transporter regulation mechanisms in HNSCC,
focusing on the role of the nuclear pregnane X receptor
(PXR, NR1I2) and epigenetic mechanisms. Real-time
RT-PCR revealed increased mRNA expression of solute
carrier (SLC) family membrane transporters SLCO1A2
and SLCO1B3 and decreased expression of SLC and
ATP-binding cassette (ABC) transporters SLCO2B1,
SLCO2A1, and ABCC3 in human HNSCC tumors. ABCC3
and SLCO2A1 promoter CpG islands lacked hypermethy-
lation. The DNA methyltransferase inhibitor decitabine
markedly induced expression of transporters and NR1I2 in
HNSCC-derived cell lines, and cotreatment with the proto-
typical PXR activator rifampicin signiﬁcantly reversed
decitabine-induced ABCC3 and SLCO2A1 expression. In
summary, altered expression of drug transporters in HNSCC
tumor tissues might be predictive of the outcome of HNSCC
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